Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results

Like
Comment
Favorite

Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results

MT Newswires Live2024-10-23

Top-line results from Zhaoke Ophthalmology's (HKG:6622) phase III clinical trial of its NVK002 showed "strong" safety and high patient compliance, according to a Wednesday bourse disclosure.

NVK002 is indicated for the treatment of myopia progression in Chinese children and adolescents.

The two-year trial involved 18 centers and enrolled 777 patients.

Shares of the ophthalmic pharmaceutical company closed over 2% higher on Wednesday.

Price (HKD): $1.36, Change: $+0.030, Percent Change: +2.26%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2477016584?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-10-23 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477016584","market":"hk","top_or_hot":-1,"title":"Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results","media":"MT Newswires Live","content":"<html><body><p> Top-line results from Zhaoke Ophthalmology's (HKG:6622) phase III clinical trial of its NVK002 showed \"strong\" safety and high patient compliance, according to a Wednesday bourse disclosure.</p><p>NVK002 is indicated for the treatment of myopia progression in Chinese children and adolescents.</p><p>The two-year trial involved 18 centers and enrolled 777 patients.</p><p>Shares of the ophthalmic pharmaceutical company closed over 2% higher on Wednesday.</p><p>Price (HKD): $1.36, Change: $+0.030, Percent Change: +2.26%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-23 20:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Top-line results from Zhaoke Ophthalmology's (HKG:6622) phase III clinical trial of its NVK002 showed \"strong\" safety and high patient compliance, according to a Wednesday bourse disclosure.</p><p>NVK002 is indicated for the treatment of myopia progression in Chinese children and adolescents.</p><p>The two-year trial involved 18 centers and enrolled 777 patients.</p><p>Shares of the ophthalmic pharmaceutical company closed over 2% higher on Wednesday.</p><p>Price (HKD): $1.36, Change: $+0.030, Percent Change: +2.26%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2477016584","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477016584","pubTimestamp":1729687820,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Top-line results from Zhaoke Ophthalmology's  phase III clinical trial of its NVK002 showed \"strong\" safety and high patient compliance, according to a Wednesday bourse disclosure.NVK002 is indicated for the treatment of myopia progression in Chinese children and adolescents.The two-year trial involved 18 centers and enrolled 777 patients.Shares of the ophthalmic pharmaceutical company closed over 2% higher on Wednesday.Price : $1.36, Change: $+0.030, Percent Change: +2.26%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4526":"热门中概股","HKD":"尚乘数科","06622":"兆科眼科-B","BK1574":"生物医药B类股","BK4023":"应用软件","BK1583":"高瓴概念","BK1587":"次新股","BK1191":"制药","BK4588":"碎股"},"translate_title":"兆科眼科近视进展药物3期试验显示积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":0.9,"HKD":1},"content_text":"Top-line results from Zhaoke Ophthalmology's (HKG:6622) phase III clinical trial of its NVK002 showed \"strong\" safety and high patient compliance, according to a Wednesday bourse disclosure.NVK002 is indicated for the treatment of myopia progression in Chinese children and adolescents.The two-year trial involved 18 centers and enrolled 777 patients.Shares of the ophthalmic pharmaceutical company closed over 2% higher on Wednesday.Price (HKD): $1.36, Change: $+0.030, Percent Change: +2.26%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}